🌷Late breaking news at #ECTRIMS2022 @Iamsterdam Surprising or not? Propensity matched study of #HSCT versus #Natalizumab in #progressive #MS revealed no difference in efficacy. Early treatment best, applies to both💡 pic.twitter.com/X41ivERaVk

— Klaus Schmierer🎗️🇺🇦 (@KlausSchmierer) October 28, 2022